Quote this publication Share Print

ULTIBRO BREEZHALER (indacaterol, glycopyrronium) long-acting bronchodilator

RESPIRATORY MEDICINE - Update
Opinions on drugs - Posted on Mar 29 2018

Reason for request

Re-assessment of the actual benefit and the improvement in actual benefit

Moderate clinical benefit in continuous bronchodilator treatment of chronic obstructive pulmonary disease

 

  • ULTIBRO BREEZHALER has Marketing Authorisation in continuous bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
  • The results of new data have led to the conclusion that this fixed combination of two long-acting bronchodilators has a moderate clinical benefit in this indication (and no longer substantial) in a population restricted to patients with moderate to very severe COPD whose symptoms are already controlled by the combination of indacaterol and glycopyrronium separately administered.
  • ULTIBRO BREEZHALER is more specifically for patients with moderate to very severe COPD who have associated persistent dyspnoea despite use of a long-acting bronchodilator in monotherapy.

 


Clinical Benefit

Moderate

-


Clinical Added Value

no clinical added value

-


Contact Us

Évaluation des médicaments